Stocklytics Platform
Asset logo for symbol CNTB
Connect Biopharma Holdings Limited
CNTB44
$1.20arrow_drop_down2.43%-$0.03
Penny Stock
Asset logo for symbol CNTB
CNTB44

$1.20

arrow_drop_down2.43%

Performance History

Chart placeholder
Key Stats
Open$1.18
Prev. Close$1.23
EPS-0.39
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$67.96M
PE Ratio-
LOWHIGH
Day Range1.13
1.27
52 Week Range0.53
2.84
Ratios
Revenue-
EBITDA Margin %-
EPS-0.39

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Connect Biopharma Holdings Limited (CNTB)

Connect Biopharma Holdings Limited (CNTB) is a biopharmaceutical company that specializes in the discovery and development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company focuses on the development of compounds that target the IL-4 and IL-13 pathways, which are involved in various immune-mediated diseases. Connect Biopharma's lead product candidate, CBP-201, is a potential first-in-class antibody that is being evaluated in clinical trials for the treatment of moderate-to-severe atopic dermatitis.
CBP-201 has demonstrated promising results in early clinical trials, showing significant improvement in disease symptoms and skin lesions. The drug works by selectively targeting and neutralizing IL-4 and IL-13, which are key drivers of inflammation and allergic responses. By inhibiting these pathways, CBP-201 has the potential to provide long-term relief to patients suffering from atopic dermatitis.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Zheng Wei Ph.D.
Headquarters
San Diego
Employees
100
Exchange
NASDAQ
add Connect Biopharma Holdings Limited to watchlist

Keep an eye on Connect Biopharma Holdings Limited

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Connect Biopharma Holdings Limited's (CNTB) price per share?

The current price per share for Connect Biopharma Holdings Limited (CNTB) is $1.2. The stock has seen a price change of -$0.03 recently, indicating a -2.44% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Connect Biopharma Holdings Limited (CNTB)?

For Connect Biopharma Holdings Limited (CNTB), the 52-week high is $2.84, which is 136.67% from the current price. The 52-week low is $0.54, the current price is 124.3% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Connect Biopharma Holdings Limited (CNTB) a growth stock?

Connect Biopharma Holdings Limited (CNTB) has shown an average price growth of 0.41% over the past three years. It has received a score of 14 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Connect Biopharma Holdings Limited as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Connect Biopharma Holdings Limited (CNTB) stock price performance year to date (YTD)?

As of the latest data, Connect Biopharma Holdings Limited (CNTB) has a year-to-date price change of -2.44%. Over the past month, the stock has experienced a price change of 1.69%. Over the last three months, the change has been -27.27%. Over the past six months, the figure is -7.69%.
help

Is Connect Biopharma Holdings Limited (CNTB) a profitable company?

Connect Biopharma Holdings Limited (CNTB) has a net income of -$59.38M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 24.64% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$64.85M. Furthermore, the EBITDA is -$24.95M.
help

What is the market capitalization of Connect Biopharma Holdings Limited (CNTB)?

Connect Biopharma Holdings Limited (CNTB) has a market capitalization of $67.96M. The average daily trading volume is 22.94K, indicating the stock's liquidity and investor engagement.

News

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
CALENDAR OF EVENTS
MAJOR SHAREHOLDER ANNOUNCEMENTS
7/1/2024

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CHANGES IN COMPANY'S OWN SHARES
6/12/2024

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Connect Biopharma Announces New Leadership and Chair of the Board of Directors
DIRECTORS AND OFFICERS
6/12/2024

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
CALENDAR OF EVENTS
5/22/2024

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
CALENDAR OF EVENTS
HEALTH
5/7/2024

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
EARNINGS RELEASES AND OPERATING RESULTS
4/16/2024

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocks Screeners

Other Screeners

ETFs Screeners

Solutions

Real-Time Stock AlertsTechnical SignalsSTKS™ ScoreSmart PortfolioCandle and Chart PatternsStock ScreenersAI Stock PicksTrading Signals

Features

WatchlistPortfolioAlertsCustom ScreenerAI Stock Picks

Company

PlansNewsSitemap
Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media